|
|
Nuvaring
|
|
The NuvaRing is a once-a-month combined contraceptive
vaginal ring, which was approved for use the United States in October. It is a transparent,
flexible ring that provides month-long birth control by emitting a continuous dose
of estrogen and progestin for 21 days. However, since the NuvaRing hit the market
it has been the subject of many lawsuits related to blood clots and has also been
blamed for 12 deaths nationwide. The NuvaRing is manufactured by Organon Pharmaceuticals
USA inc., Organon USA Inc., Organon International Inc, Schering Plough Corp., and
Akzo Nobel NV.
NuvaRing releases a form of progestin called desogentrel
which has been shown to increase the risk of venous thromboembolism, a potentially
fatal type of blood clot. In 2007, the consumer advocacy group Public Citizen asked
federal regulators to ban oral contraceptives that contained forms of desogestral
because it has been implicated in a higher risk of strokes, blood clots and other
cardiovascular problems. NuvaRing releases approximately 120 micrograms of etonogestral,
an active desogestral metabolite, per day, which is a relatively high dose of this
dangerous hormone.
Blood clots, also known as thrombosis, can occur when
blood cells clump together in the vein, which restricts blood flow. If a blood clot
forms in the deep veins of the legs, pelvis, or arms, known as deep vein thrombosis,
this can severely restrict blood flow to the heart, lungs or brain. This can lead
to serious and potentially fatal injuries.
IF YOU ARE CURRENTLY USING NUVARING AND HAVE CONCERNS ABOUT ITS SAFETY, YOU
SHOULD CONSULT WITH YOUR DOCTOR REGARDING YOUR TREATMENT OPTIONS.
For a free case evaluation, please call 1-800-404-9281 or visit
www.nuvaringnews.com.
|
|
